AstraZeneca PLC Announces Q1 2016 Results

29 April 2016

Financial Summary

+-------------------+-----+----+------+
|                   | $m  | % change  |
+-------------------+-----+----+------+
|                   |     |CER1|Actual|
+-------------------+-----+----+------+
|Total Revenue2     |6,115| 5  |  1   |
+-------------------+-----+----+------+
|                   |     |    |      |
+-------------------+-----+----+------+
|Core3 Op. Profit   |1,593|(8) | (12) |
+-------------------+-----+----+------+
|Core EPS           |$0.95|(7) | (12) |
+-------------------+-----+----+------+
|                   |     |    |      |
+-------------------+-----+----+------+
|Reported Op. Profit|1,038| 17 |  11  |
+-------------------+-----+----+------+
|Reported EPS       |$0.51| 26 |  17  |
+-------------------+-----+----+------+



  · Total Revenue grew by 5%, driven by a significant increase in
Externalisation Revenue

  · Core R&D costs increased by 15%, reflecting recent acquisitions; Core R&D
costs declined versus Q4 2015

  · Core SG&A costs fell by 6% and represented 35% of Total Revenue (Q1 2015:
39%)

  · Core EPS declined by 7%, reflecting a significant reduction in Other
Operating Income

  · Reported Operating Profit grew by 17% to $1,038m. Reported EPS grew by 26%
to $0.51

  · FY 2016 CER guidance unchanged

Commercial Highlights

The Growth Platforms grew by 6%, representing 56% of Total Revenue:

1. Respiratory: +2%. Growth of Pulmicort and newly-acquired medicines offset by
a decline in sales of Symbicort

2. Brilinta/Brilique: +46%. Continued encouraging progress; post-MI approval in
the EU

3. Diabetes: +23%. Strong sales growth included an increase of +65% in Emerging
Markets.

Global Farxiga/Forxiga growth of 128%

4. Emerging Markets: +6%. Good China sales growth of +11%; slowdowns in other
regions

5. Japan: -7%, reflecting destocking ahead of mandated biennial price reductions
from April 2016

6. New Oncology: Contributed $99m. Launch of Tagrisso in key markets progressing
well

Click on, or paste the following link into your web browser, to view the
associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/7481W_1-2016-4-28.pdf